http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010530862-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-422 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-04 |
| filingDate | 2008-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2010-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2010530862-A |
| titleOfInvention | Isoxazole-imidazole derivatives |
| abstract | The present invention relates to isoxazole-imidazole derivatives having affinity and selectivity for GABA Aα5 receptor binding site, their production, pharmaceutical compositions containing them, and their use as pharmaceuticals. The active compounds of the present invention are useful as cognitive enhancers or in the treatment of cognitive disorders such as Alzheimer's disease. In particular, the invention provides an aryl-isoxazol-4-yl-imidazole derivative of formula I: wherein R 1 , R 2 and R 3 are as described in the specification. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014502279-A |
| priorityDate | 2007-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 279.